<DOC>
	<DOCNO>NCT01061840</DOCNO>
	<brief_summary>Autologous Vigil™ vaccine express rhGMCSF bi-shRNAfurin Vigil™ plasmid . The GMCSF protein potent stimulator immune system , recruit immune effector site intradermal injection promote antigen presentation . The furin bifunctional shRNA block furin protein production post transcriptional translational level . This decrease furin turn decrease conversion proforms TGFβ1 TGFβ2 protein . Also , reduce furin protein level negative feedback inhibition TGFβ1 TGFβ2 gene expression , decrease level mRNAs . The result decrease TGFβ1 TGFβ2 proteins reduces local immunosuppression cause promote tumor surface antigen MHC protein display .</brief_summary>
	<brief_title>Trial Bi-shRNA-furin Granulocyte Macrophage Colony Stimulating Factor ( GMCSF ) Augmented Autologous Tumor Cell Vaccine Advanced Cancer</brief_title>
	<detailed_description>Preliminary study variety vaccine suggest target accessibility ( potential immunogenicity ) variety solid tumor immune direct approach . In effort overcome limitation immunostimulatory cancer vaccine , design novel autologous vaccine address inability fully identify cancer associate antigen , antigen recognition immune system ( i.e . antigen immunogen ) , effector potency , cancer-induced resistance . We complete clinical investigation use two different gene vaccine approach induce enhancement tumor antigen recognition demonstrate therapeutic efficacy . Specifically , use GMCSF gene transduce vaccine ( GVAX® ) TGFβ2 antisense gene vaccine ( Lucanix® ) , separate trial , demonstrate similar beneficial effect without evidence significant toxicity advance cancer patient . The GMCSF transgene directly stimulate increased expression tumor antigen ( ) enhance dendritic cell migration vaccination site . TGFβ2 blockade follow intracellular TGFβ2 antisense gene expression reduces production immune inhibiting activity vaccine site . This appear one primary mechanism inhibition immune responsiveness glioblastoma lung cancer . In subsequent Phase I trial combine active principle one autologous vaccine , TAG . TAG vaccine excellent safety profile first nineteen patient treat ( enrollment open solid tumor ) one document CR ( melanoma ) . However , TGFβ1 dominant TGFβ family inhibitory effector majority solid tumor . We describe unique method inhibit TGFβ1 TGFβ2 RNA interference Furin . We harvest autologous cancer cell patient advanced refractory cancer . We construct bi-shRNAfurin / GMCSF ( Vigil™ ) expression vector plasmid successfully demonstrate preclinical activity vector function follow transfection electroporation irradiation ex vivo autologous tumor cell .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>Tissue Procurement 1 . Presumptive histologically confirm advanced metastatic noncurable solid tumor ( limited single lesion , may candidate curative surgery radiation therapy ) . 2 . For purpose Pediatric study patient histologic diagnosis ESFT include : Ewing 's sarcoma primitive neuroectodermal tumor ( malignant neuroepithelioma ) bone soft tissue , Askin 's tumor chest central nervous system tumor eligible . 3 . Patients recurrent refractory ESFT . Patients de novo poor prognosis/high risk ESFT : ( Eligible vaccine manufacturing diagnosis ONLY ELIGIBLE FOR IMMUNOTHERAPY IF DEMONSTRATES PERSISTENT/RECURRENT/ REFRACTORY DISEASE ) 1 . Large tumor &gt; 8 cm 2 . Pelvic osseous tumor ANY SIZE 3 . Bilateral pulmonary metastasis 4 . &gt; 2 unilateral pulmonary metastasis 4 . Clinically ( medically ) indicate procedure ( i.e . biopsy lesion recurrent disease , palliative management via resection , thoracentesis , etc . ) collect tumor sufficient quantity ( `` golf ball size '' estimate weight 1030 gram , pleural , and/or ascites fluid estimate volume ≥ 500 mL ) vaccine processing . 5 . For ESFT patient age ≥12 year . 6 . Age ≥18 year ( nonESFT candidate ) ECOG performance status ( PS ) 01 . Pediatric patient Lansky Karnofsky Performance Status Scale ≥ 50 % . 7 . Estimated &gt; 4 month survival probability . 8 . Ability understand willingness sign write informed consent document . Pediatric patient must sign assent parent legal guardian sign write informed consent . 1 . Histologically confirm advanced metastatic noncurable solid tumor ( limited single lesion may candidate curative surgery radiation therapy ) . Successful vaccine manufacture result tissue/fluid obtain follow major organ system : digestive , endocrine , reproductive , respiratory , urinary.Individuals manufacture CLPTL 105 ( Phase II Ovarian ) may eligible enrollment without advanced metastatic disease . 2 . Patients well differentiate thyroid cancer eligible protocol follow : 1 . Surgically unresectable locally recurrent disease and/or metastatic disease follow RAI ablation ( locally recurrent ultrasound ( US ) positive , baseline FDGPET MRI obtain ) . 2 . Patients microscopic and/or gross extra thyroidal disease extension without RAI uptake ) FDGPET positive disease b ) suppress thyroglobulin &gt; 1 ng/mL c ) stimulate thyroglobulin &gt; 10 ng/L . 3 . Patients tracheal/esophageal involvement . High mitotic activity necrosis pathology exclude study . Note : Categories b , patient follow use US locally addition standard diagnostic followup menu , US positive , FDGPET MRI obtain . If negative , rise thyroglobulin titer require case response monitor continue US suppress and/or stimulate thyroglobulin . Thyroglobulin titer use antithyroglobulin antibody present ) . 3 . Completed acceptable therapy curative intent current standard care respective disease . If conventional therapy available , patient may participate review sponsor . 4 . Recovered clinically relevant toxicity relate prior therapy 5 . Patients allow participate follow single prior CNS treatment stereotactic radiotherapy whole brain irradiation stable without steroid requirement ≥2 month follow ≥2 prior CNS treatment stereotactic radiotherapy whole brain irradiation stable without steroid requirement ≥4 month . 6 . For ESFT patient age ≥12 year . 7 . Age ≥18 year ( nonESFT candidate ) 8 . ECOG performance status ( PS ) 01.Pediatric patient Lansky Karnofsky Performance Status Scale ≥ 50 % . 9 . Estimated &gt; 4 month survival probability . 10 . Normal organ marrow function define : Absolute granulocyte count ≥ 1,500/mm3 Absolute lymphocyte count ≥ 500/mm3 Platelets ≥ 100,000/mm3 Total bilirubin ≤2 mg/dL AST ( SGOT ) /ALT ( SGPT ) &lt; 2x institutional upper limit normal Creatinine &lt; 1.5 mg/dL 11 . Ability understand willingness sign write informed consent document . Pediatric patient must sign assent parent legal guardian sign write informed consent . 12 . Negative pregnancy test . 13 . Patients must `` statin '' drug ≥2 week prior initiation therapy . 1 . Surgery involve general anesthesia , radiotherapy , steroid therapy , immunotherapy within 4 week prior vaccination . Chemotherapy within 3 week prior enter study . Palliative radiotherapy allowable . Collection lumenal tissue vaccine manufacture must avoid . 2 . Patients must receive investigational agent within 30 day prior vaccination . 3 . Concurrent tumorspecific hormonal therapy antiestrogens . ( Individuals manufacture CLPTL 105 ( Phase II Ovarian ) subject exclusion ) . 4 . Patients know active symptomatic brain metastasis prior vaccination . 5 . Patients compromise pulmonary disease . 6 . Short term ( &lt; 30 day ) concurrent systemic steroid ≤0.25 mg/kg prednisone per day ( maximum 7.5 mg/day ) bronchodilator ( inhaled steroid ) permit ; steroid regimen and/or immunosuppressive exclude receive vaccine . Patients require steroid follow previous CNS radiation metastatic disease exclude . 7 . Prior splenectomy unless HowellJolly body absent . 8 . Prior malignancy ( exclude nonmelanoma carcinomas skin ) unless remission 2 year . 9 . Kaposi 's Sarcoma . 10 . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 11 . Patients pregnant nursing . 12 . Patients know HIV . 13 . Patients chronic Hepatitis B C infection . For patient hepatocellular carcinoma ( HCC ) , presence chronic HBV HCV NOT exclusion . Patients must viral titer &lt; 50 IU/ml x 2 minimum 2 week apart . 14 . Patients uncontrolled autoimmune disease .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ewings Sarcoma</keyword>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>Liver Cancer</keyword>
</DOC>